Cenacchi, V.; Furlanis, G.; Menichelli, A.; Lunardelli, A.; Pesavento, V.; Manganotti, P. Co-ultraPEALut in Subjective Cognitive Impairment Following SARS-CoV-2 Infection: An Exploratory Retrospective Study. Brain Sci.2024, 14, 293.
Cenacchi, V.; Furlanis, G.; Menichelli, A.; Lunardelli, A.; Pesavento, V.; Manganotti, P. Co-ultraPEALut in Subjective Cognitive Impairment Following SARS-CoV-2 Infection: An Exploratory Retrospective Study. Brain Sci. 2024, 14, 293.
Cenacchi, V.; Furlanis, G.; Menichelli, A.; Lunardelli, A.; Pesavento, V.; Manganotti, P. Co-ultraPEALut in Subjective Cognitive Impairment Following SARS-CoV-2 Infection: An Exploratory Retrospective Study. Brain Sci.2024, 14, 293.
Cenacchi, V.; Furlanis, G.; Menichelli, A.; Lunardelli, A.; Pesavento, V.; Manganotti, P. Co-ultraPEALut in Subjective Cognitive Impairment Following SARS-CoV-2 Infection: An Exploratory Retrospective Study. Brain Sci. 2024, 14, 293.
Abstract
Neurological involvement following COronaVIrus Disease 19 (COVID-19) is thought to have a neuroinflammatory etiology. Co-ultraPEALut (an antiinflammatory molecule) and luteolin (an antioxidant) yielded promising results as neuroinflammation antagonists. This study aimed at describing cognitive impairment in post-COVID patient treated with co-ultraPEALut. Montreal Cognitive Assessment (MoCA), Prospective-Retrospective Memory Questionnaire (PRMQ), Fatigue Severity Scale (FSS) and a subjective evaluation were administered at baseline and after 10 months. Co-ultraPEALut-treated patients were retrospectively compared with controls. 26 co-ultraPEALut-treated patients showed significant improvement in PRMQ (T0: 51.94±10.55, T1: 39.67±13.02, p
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
